**This article has been corrected:** The correct Materials and Methods and Figure [2](#F2){ref-type="fig"} are given below: The authors declare that these corrections do not change the results or conclusions of this paper.

**Luciferase reporting assay**

The 3' UTR of BACE1 and the CMV promoter were amplified from human chromosomal DNA and pcDNA3.1 (+) and cloned into the pGL3-luciferase basic vector (Promega, Madison, WI, USA). Sequences of primers and cloning strategy are available on request. For the luciferase assays, 50 nM of miR-124 mimics or scrambled RNA were co-transfected with the reporter vector and the Renilla control vector (Promega, Madison, WI, USA) into the HEK293 cells by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). 24 h post transfection, the measurements were performed using the Dual luciferase re-porter assay kit (Promega, Madison, WI, USA). Or the HEK293 cells post the transfection for 24 h was lyzed for western blot analysis.

![(**A**) MTT assay results showed that Aβ inhibited the viability of SH-SY5Y cells and downregulation of BACE1 enhanced the inhibitory effects of Aβ; (**B**) downregulation of miR-124 relieved Aβ-induced viability inhibition of SH-SY5Y cells; (**C**) flow cytometric analysis results showed that Aβ-induced apoptosis of SH-SY5Y cells and downregulation of BACE1 enhanced the induced effects of Aβ; (**D**) downregulation of miR-124 decreased apoptosis of SH-SY5Y cells in the presence of Aβ.](oncotarget-09-24871-g002){#F2}
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